U.S. market Open. Closes in 3 hours 26 minutes

PTGX | Protagonist Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 38.17 - 39.24
52 Week Range 24.22 - 48.89
Beta 2.34
Implied Volatility 68.70%
IV Rank 86.75%
Day's Volume 73,149
Average Volume 693,705
Shares Outstanding 59,598,000
Market Cap 2,292,437,070
Sector Healthcare
Industry Biotechnology
IPO Date 2016-08-11
Valuation
Profitability
Growth
Health
P/E Ratio 14.04
Forward P/E Ratio N/A
EPS 2.74
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 126
Country USA
Website PTGX
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
*Chart delayed
Analyzing fundamentals for PTGX we got that it has average fundamentals where Valuation is considered to be slightly overvalued, Profitability is stunning wealthy, Growth is bad and Health is passable. For more detailed analysis please see PTGX Fundamentals page.

Watching at PTGX technicals we can see that long-term trend is bullish, while middle-term trend is bearish, as well as bearish short-term trend. More technicals details can be found on PTGX Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙